What is the problem with Bayer Trasylol (Bayer aprotinin)?
Two non-profit biomedical research organizations conducted the independent observational study (“Trasylol Bayer report”). The organizations dedicated to saving and extending lives are Ischemia Research and Education Foundation and the McSPI Research Group. Principal scientist, Dennis T. Mangano, Ph.D., M.D., advocates that the “Trasylol Bayer report” provides compelling evidence of Bayer aprotinin’s risks and strongly suggests discontinuing use. He recommends replacing Bayer aprotinin with two alternative generic drugs that are far less costly, much safer but for some reason marketed less. Raising more concerns aprotinin has been on the market three times longer than Vioxx exposing patients to life-threatening complications. According to the study that examined 4,374 coronary artery bypass surgery patients at hospitals around the world, replacing Bayer aprotinin with one of two safe generic drugs would annually: • Prevent as many as 11,050 dialysis complications • Save at least $1 bill
